BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y

111
4
Favorite

BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y

seekingalpha2022-08-04

U.S.-listed shares of BeiGene rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

111

Report

Comment（4）

ericbqlee
·2022-08-05
😀
Reply
1
Report
SPOT_ON
·2022-08-05
Ok
Reply
3
Report
ARIESan
·2022-08-05
Very nice 👍
Reply
1
Report
Prakash450
·2022-08-05
[Smile]
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2256037249?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-08-04 22:24","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2256037249","market":"us","top_or_hot":-1,"title":"BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y","media":"seekingalpha","content":"<div>\n<p>U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and ...</p>\n\n<a href=\"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 22:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and ...</p>\n\n<a href=\"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BGNE","symbol_name":"百济神州","start_time":0,"source_url":"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy","article_id":"2256037249","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2256037249","pubTimestamp":1659623088,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BGNE":"百济神州"},"translate_title":"第二季度收入Y/Y增长逾一倍后，百济神州股价上涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":0.9},"content_text":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.BGNE's quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.The bulk of BGNE's Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:Global sales of BeiGene's (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.Sales of BGNE's other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab,\" BeiGene CEO John Oyler said in the earnings report.Up to Wednesday's close, BGNE American depositary shares have lost 37.4% YTD.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9902394685,"gmtCreate":1659652656449,"gmtModify":1705588305706,"author":{"id":"4101424154342900","authorId":"4101424154342900","name":"ericbqlee","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4101424154342900","authorIdStr":"4101424154342900"},"htmlText":"😀","listText":"😀","text":"😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9902394685","repostId":2256037249,"repostType":4,"repost":{"id":"2256037249","pubTimestamp":1659623088,"share":"https://ttm.financial/m/news/2256037249?lang=&edition=fundamental","pubTime":"2022-08-04 22:24","market":"us","language":"en","title":"BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2256037249","media":"seekingalpha","summary":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the ","content":"<html><head></head><body><p>U.S.-listed shares of <a href=\"https://laohu8.com/S/BGNE\">BeiGene </a> rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.</p><p>BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.</p><p>BGNE&#39;s quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.</p><p>The bulk of BGNE&#39;s Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:</p><ul><li>Global sales of BeiGene&#39;s (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.</li><li>Sales of BGNE&#39;s other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.</li><li>Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.</li><li>Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.</li></ul><p>“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab,&#34; BeiGene CEO John Oyler said in the earnings report.</p><p>Up to Wednesday&#39;s close, BGNE American depositary shares have lost 37.4% YTD.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 22:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and ...</p>\n\n<a href=\"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BGNE":"百济神州"},"source_url":"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2256037249","content_text":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.BGNE's quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.The bulk of BGNE's Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:Global sales of BeiGene's (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.Sales of BGNE's other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab,\" BeiGene CEO John Oyler said in the earnings report.Up to Wednesday's close, BGNE American depositary shares have lost 37.4% YTD.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9902306805,"gmtCreate":1659651588110,"gmtModify":1705586706238,"author":{"id":"3582922989777578","authorId":"3582922989777578","name":"SPOT_ON","avatar":"https://static.tigerbbs.com/080f029371339d9db26930961de6adb1","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":4,"crmLevelSwitch":1,"idStr":"3582922989777578","authorIdStr":"3582922989777578"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9902306805","repostId":2256037249,"repostType":4,"repost":{"id":"2256037249","pubTimestamp":1659623088,"share":"https://ttm.financial/m/news/2256037249?lang=&edition=fundamental","pubTime":"2022-08-04 22:24","market":"us","language":"en","title":"BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2256037249","media":"seekingalpha","summary":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the ","content":"<html><head></head><body><p>U.S.-listed shares of <a href=\"https://laohu8.com/S/BGNE\">BeiGene </a> rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.</p><p>BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.</p><p>BGNE&#39;s quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.</p><p>The bulk of BGNE&#39;s Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:</p><ul><li>Global sales of BeiGene&#39;s (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.</li><li>Sales of BGNE&#39;s other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.</li><li>Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.</li><li>Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.</li></ul><p>“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab,&#34; BeiGene CEO John Oyler said in the earnings report.</p><p>Up to Wednesday&#39;s close, BGNE American depositary shares have lost 37.4% YTD.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 22:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and ...</p>\n\n<a href=\"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BGNE":"百济神州"},"source_url":"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2256037249","content_text":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.BGNE's quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.The bulk of BGNE's Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:Global sales of BeiGene's (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.Sales of BGNE's other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab,\" BeiGene CEO John Oyler said in the earnings report.Up to Wednesday's close, BGNE American depositary shares have lost 37.4% YTD.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9902979646,"gmtCreate":1659650072587,"gmtModify":1705586619758,"author":{"id":"4087545408973980","authorId":"4087545408973980","name":"ARIESan","avatar":"https://static.tigerbbs.com/ab7b9364a4791173d66fbb5fda8ef925","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087545408973980","authorIdStr":"4087545408973980"},"htmlText":"Very nice 👍&nbsp;","listText":"Very nice 👍&nbsp;","text":"Very nice 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9902979646","repostId":2256037249,"repostType":4,"repost":{"id":"2256037249","pubTimestamp":1659623088,"share":"https://ttm.financial/m/news/2256037249?lang=&edition=fundamental","pubTime":"2022-08-04 22:24","market":"us","language":"en","title":"BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2256037249","media":"seekingalpha","summary":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the ","content":"<html><head></head><body><p>U.S.-listed shares of <a href=\"https://laohu8.com/S/BGNE\">BeiGene </a> rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.</p><p>BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.</p><p>BGNE&#39;s quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.</p><p>The bulk of BGNE&#39;s Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:</p><ul><li>Global sales of BeiGene&#39;s (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.</li><li>Sales of BGNE&#39;s other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.</li><li>Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.</li><li>Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.</li></ul><p>“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab,&#34; BeiGene CEO John Oyler said in the earnings report.</p><p>Up to Wednesday&#39;s close, BGNE American depositary shares have lost 37.4% YTD.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 22:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and ...</p>\n\n<a href=\"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BGNE":"百济神州"},"source_url":"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2256037249","content_text":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.BGNE's quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.The bulk of BGNE's Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:Global sales of BeiGene's (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.Sales of BGNE's other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab,\" BeiGene CEO John Oyler said in the earnings report.Up to Wednesday's close, BGNE American depositary shares have lost 37.4% YTD.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9902923349,"gmtCreate":1659631408286,"gmtModify":1706067637831,"author":{"id":"4112843070972822","authorId":"4112843070972822","name":"Prakash450","avatar":"https://community-static.tradeup.com/news/47e0b474a4a9336cf7c15390d66ec071","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4112843070972822","authorIdStr":"4112843070972822"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9902923349","repostId":2256037249,"repostType":4,"repost":{"id":"2256037249","pubTimestamp":1659623088,"share":"https://ttm.financial/m/news/2256037249?lang=&edition=fundamental","pubTime":"2022-08-04 22:24","market":"us","language":"en","title":"BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2256037249","media":"seekingalpha","summary":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the ","content":"<html><head></head><body><p>U.S.-listed shares of <a href=\"https://laohu8.com/S/BGNE\">BeiGene </a> rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.</p><p>BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.</p><p>BGNE&#39;s quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.</p><p>The bulk of BGNE&#39;s Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:</p><ul><li>Global sales of BeiGene&#39;s (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.</li><li>Sales of BGNE&#39;s other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.</li><li>Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.</li><li>Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.</li></ul><p>“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab,&#34; BeiGene CEO John Oyler said in the earnings report.</p><p>Up to Wednesday&#39;s close, BGNE American depositary shares have lost 37.4% YTD.</p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene Shares Rise After Q2 Revenue More Than Doubles Y/Y\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 22:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and ...</p>\n\n<a href=\"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BGNE":"百济神州"},"source_url":"https://seekingalpha.com/news/3867312-us-listed-shares-of-beigene-rise-after-q2-revenue-more-than-doubles-yy","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2256037249","content_text":"U.S.-listed shares of BeiGene  rose as much as 3% to $174.72 in Thursday morning trading, after the company reported Q2 revenue that more than doubled Y/Y.BGNE stock had pared most of the gains and was last trading 1.7% higher as of 1010 ET.BGNE's quarterly revenue of $341.57M rose 127.7% Y/Y and beat estimates by $30.5M. However, Q2 GAAP earnings per American depositary share of -$5.56 missed expectations by $1.45.The bulk of BGNE's Q2 sales came from product revenue of $304.5M (vs. $138.6M last year), which included:Global sales of BeiGene's (BGNE) cancer drug Brukinsa, which came in at $128.7M, a significant increase from $42.4M last year.Sales of BGNE's other cancer medication, tislelizumab, of $104.9M in China, compared to $74.9M last year.Sales of products in-licensed from Amgen (AMGN) of $29.5M in China vs. $3.3M a year ago.Sales of products in-licensed from Bristol-Myers Squibb (BMY) of $23.4M in China, a Y/Y gain from $13.4M.“We made significant progress in our mission to reach far more cancer patients with innovative and affordable medicines, with growth in product revenues across our portfolio, driven primarily by our internally developed medicines, Brukinsa and tislelizumab,\" BeiGene CEO John Oyler said in the earnings report.Up to Wednesday's close, BGNE American depositary shares have lost 37.4% YTD.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":111,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}